首页> 外文期刊>Clinical Biochemistry >Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction
【24h】

Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction

机译:心脏型脂肪酸结合蛋白(H-FABP)和肌钙蛋白联合用于急性心肌梗死的早期诊断的严格审查和荟萃分析

获取原文
获取原文并翻译 | 示例
       

摘要

An early diagnosis is crucial for effective triage and management of patients with suspected acute myocardial infarction (AMI). Although troponin testing is the cornerstone of diagnosis, the sensitivity of this biomarker is still suboptimal at patient admission. The heart-type fatty acid binding protein (H-FABP) is an early and sensitive biomarker of myocardial ischemia, whose appropriate setting is in combination with troponin testing. We performed a systematic review and meta-analysis of articles that have assessed the combination of troponin and H-FABP in the early diagnosis of AMI. Eight studies, totaling 2735 patients, met the inclusion criteria but none of them used a high-sensitivity troponin immunoassay. The between-study variation was high (98.5%), and attributable to heterogeneity. When considered alone, troponin exhibited a significantly greater pooled area under the curve (AUC) than H-FABP alone (0.820 versus 0.784; p < 0.001). The pooled specificity was also higher for troponin alone than for H-FABP alone (0.94 versus 0.83; p < 0.001), whereas the cumulative sensitivity was lower for troponin than for H-FABP (0.73 versus 0.80; p. =0.02). The combination of both biomarkers exhibited a greater AUC than troponin alone (0.881; p < 0.001), as well as a higher pooled sensitivity (0.91; p < 0.001), which was however counterbalanced by a lower specificity (0.82; p < 0.001). These results attest that the combination of H-FABP with a conventional troponin immunoassay seems advantageous for increasing the sensitivity of the former biomarker, at the expense of a lower specificity. The introduction of H-FABP testing would hence require careful assessment of laboratory data or clinical signs and symptoms for excluding sources of elevation different from AMI. Further studies are needed to assess the diagnostic effectiveness of combining H-FABP with a high-sensitivity troponin immunoassay.
机译:早期诊断对于可疑急性心肌梗死(AMI)患者的有效分类和治疗至关重要。尽管肌钙蛋白检测是诊断的基石,但该生物标志物的敏感性在患者入院时仍不理想。心脏型脂肪酸结合蛋白(H-FABP)是心肌缺血的早期且敏感的生物标志物,其适当设置与肌钙蛋白测试结合使用。我们对评估肌钙蛋白和H-FABP联合用于AMI早期诊断的文章进行了系统的综述和荟萃分析。八项研究(共2735例患者)符合纳入标准,但均未使用高灵敏度肌钙蛋白免疫测定法。研究之间的差异很大(98.5%),并归因于异质性。单独考虑时,肌钙蛋白的曲线下合并面积(AUC)比单独使用H-FABP的要大得多(0.820对0.784; p <0.001)。单独的肌钙蛋白的合并特异性也高于单独的H-FABP(0.94对0.83; p <0.001),而肌钙蛋白的累积敏感性低于H-FABP(0.73对0.80; p = 0.02)。两种生物标志物的组合均显示出比单独的肌钙蛋白更高的AUC(0.881; p <0.001),以及更高的合并敏感性(0.91; p <0.001),但是由于较低的特异性而被抵消(0.82; p <0.001) 。这些结果证明,H-FABP与常规肌钙蛋白免疫测定法的组合似乎有利于增加前一种生物标志物的敏感性,但以较低的特​​异性为代价。因此,引入H-FABP测试需要仔细评估实验室数据或临床体征和症状,以排除不同于AMI的高程来源。需要进一步的研究来评估将H-FABP与高敏感性肌钙蛋白免疫测定相结合的诊断效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号